ARTICLE | Clinical News
Phase III data for BMY's atazanavir
October 29, 2001 8:00 AM UTC
Bristol-Myers (BMY) said 48-week data from a Phase III trial of its atazanavir once-daily protease inhibitor showed antiviral efficacy similar to Viracept nelfinavir from Roche (SWX:ROCZ) given twice ...